T1	Participants 75 129	patients with hormone receptor-positive breast cancer:
T2	Participants 336 364	patients with breast cancer.
T3	Participants 546 563	menopausal women.
T4	Participants 725 739	Fifty patients
T5	Participants 1941 1969	patients with breast cancer.
